CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held April 29-May 2, 2019 in Washington, D.C.
- SGT-001 Cardiac and Skeletal Muscle Microdystrophin Expression and Functional Efficacy in Preclinical Models of DMD
Abstract Number: 39
Date/Time: Monday, April 29th at 11:00 a.m. ET
- Multiparameter In Vivo Screen of AncAAV Libraries in Muscle for Potency, Specificity and Impact of Disease State
Abstract Number: 376
Date/Time: Tuesday, April 30th at 4:00 p.m. ET
- Identification of Novel Muscle Specific Promoters and AAV Gene Expression in Skeletal and Cardiac Muscles
Abstract Number: 822
Date/Time: Wednesday, May 1st at 5:00-6:00 p.m. ET
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Geoffrey M. Grande, CFA